Higher prevalence of poor prognostic markers at a younger age in adult patients with myelodysplastic syndrome - evaluation of a large cohort in India.
Chromosomal abnormality
Clinical risk groups
Complex karyotype
Cytogenetic prognosis groups
Cytogenetics
Deletion 5q
IPSS-R
Monosomy 7
Myelodysplastic syndrome
Trisomy 8
Journal
Molecular cytogenetics
ISSN: 1755-8166
Titre abrégé: Mol Cytogenet
Pays: England
ID NLM: 101317942
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
08
01
2024
accepted:
15
07
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
The karyotype is a major determinant of prognosis in myelodysplastic syndrome (MDS). Details of the cytogenetic profile of MDS in South Asia are limited because cytogenetic services are not widely available. We performed a retrospective analysis of the cytogenetic and clinicopathologic profile of adult primary MDS seen consecutively at a tertiary-care centre in South India between 2003 and 2017. Patients were re-categorised according to the 2022 World Health Organisation (WHO) and the International Consensus classifications (ICC). There were 936 patients aged 18-86 years (median age 53, 65% males), with MDS with del 5q, low blasts and increased blasts in 7.5%, 58.4% and 34.1% respectively. Clonal abnormalities were seen in 55% of patients, with solitary abnormalities in 29.8% and complex karyotypes (CK, ≥ 3 abnormalities) in 15%. The most frequent abnormalities were monosomy 7/deletion 7q (16.1%), deletion 5q (14.5%), trisomy 8 (11.5%), and deletion 20q (5.1%). Cytogenetic prognosis groups were distributed as follows: very good, 2%; good, 55.6%; intermediate, 16.2%; poor, 15%; very poor, 11.2%. Clinical (IPSS-R) risk stratification (842 patients) showed: very low-risk, 3.9%; low-risk, 30.9%; intermediate-risk, 24.2%; high-risk, 21%; very high-risk, 20%. Age-adjustment (IPSS-RA) raised the very low-risk group to 12.4%; the other groups decreased by 1-3% each. The most significant finding of this cytogenetic analysis of MDS in India is that abnormal karyotypes with poor prognosis markers including monosomy 7 and CK were more frequent than in most other reports, among patients who were overall younger. Trisomy 8, deletion 20q, the IPSS-R intermediate-risk and both high-risk groups were more common than in the West. Trisomy 8 was less common than in South-East Asia while CK and deletion 20q were comparable. Evaluation of such large cohorts highlights the unique features of MDS in different parts of the world. These findings suggest that there could be differences in predisposing factors, environmental or genetic, and emphasise the need for further exploration to better understand the varied nature of MDS.
Sections du résumé
BACKGROUND
BACKGROUND
The karyotype is a major determinant of prognosis in myelodysplastic syndrome (MDS). Details of the cytogenetic profile of MDS in South Asia are limited because cytogenetic services are not widely available.
METHODS
METHODS
We performed a retrospective analysis of the cytogenetic and clinicopathologic profile of adult primary MDS seen consecutively at a tertiary-care centre in South India between 2003 and 2017. Patients were re-categorised according to the 2022 World Health Organisation (WHO) and the International Consensus classifications (ICC).
RESULTS
RESULTS
There were 936 patients aged 18-86 years (median age 53, 65% males), with MDS with del 5q, low blasts and increased blasts in 7.5%, 58.4% and 34.1% respectively. Clonal abnormalities were seen in 55% of patients, with solitary abnormalities in 29.8% and complex karyotypes (CK, ≥ 3 abnormalities) in 15%. The most frequent abnormalities were monosomy 7/deletion 7q (16.1%), deletion 5q (14.5%), trisomy 8 (11.5%), and deletion 20q (5.1%). Cytogenetic prognosis groups were distributed as follows: very good, 2%; good, 55.6%; intermediate, 16.2%; poor, 15%; very poor, 11.2%. Clinical (IPSS-R) risk stratification (842 patients) showed: very low-risk, 3.9%; low-risk, 30.9%; intermediate-risk, 24.2%; high-risk, 21%; very high-risk, 20%. Age-adjustment (IPSS-RA) raised the very low-risk group to 12.4%; the other groups decreased by 1-3% each.
CONCLUSION
CONCLUSIONS
The most significant finding of this cytogenetic analysis of MDS in India is that abnormal karyotypes with poor prognosis markers including monosomy 7 and CK were more frequent than in most other reports, among patients who were overall younger. Trisomy 8, deletion 20q, the IPSS-R intermediate-risk and both high-risk groups were more common than in the West. Trisomy 8 was less common than in South-East Asia while CK and deletion 20q were comparable. Evaluation of such large cohorts highlights the unique features of MDS in different parts of the world. These findings suggest that there could be differences in predisposing factors, environmental or genetic, and emphasise the need for further exploration to better understand the varied nature of MDS.
Identifiants
pubmed: 39334460
doi: 10.1186/s13039-024-00687-z
pii: 10.1186/s13039-024-00687-z
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21Informations de copyright
© 2024. The Author(s).
Références
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of Tumours of Haematopoietic and lymphoid tissues (revised 4th Fourth Edition). IARC: Lyon,; 2017.
Heim S. In: Mitelman F, editor. Cancer cytogenetics: chromosomal and molecular genetic aberrations of Tumor cells. Fourth ed. Wiley Blackwell; 2015.
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the Acute Leukaemias French-American-British (FAB) co-operative group. Br J Haematol. 1976;33(4):451–8. https://doi.org/10.1111/j.1365-2141.1976.tb03563.x .
doi: 10.1111/j.1365-2141.1976.tb03563.x
pubmed: 188440
Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting–Airlie House, Virginia, November, 1997. Hematol J. 2000;1(1):53–66. https://doi.org/10.1038/sj.thj.6200013 .
doi: 10.1038/sj.thj.6200013
pubmed: 11920170
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–302. https://doi.org/10.1182/blood-2002-04-1199 .
doi: 10.1182/blood-2002-04-1199
pubmed: 12239137
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51. https://doi.org/10.1182/blood-2009-03-209262 .
doi: 10.1182/blood-2009-03-209262
pubmed: 19357394
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544 .
doi: 10.1182/blood-2016-03-643544
pubmed: 27069254
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic neoplasms. Leukemia. 2022;36(7):1703–19. https://doi.org/10.1038/s41375-022-01613-1 .
doi: 10.1038/s41375-022-01613-1
pubmed: 35732831
pmcid: 9252913
Arber DA, Orazi A, Hasserjian RP, et al. International Consensus classification of myeloid neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28. https://doi.org/10.1182/blood.2022015850 .
doi: 10.1182/blood.2022015850
pubmed: 35767897
pmcid: 9479031
Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–88. https://doi.org/10.1182/blood.V89.6.2079 .
doi: 10.1182/blood.V89.6.2079
pubmed: 9058730
Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503–10. https://doi.org/10.1200/JCO.2006.08.5696 .
doi: 10.1200/JCO.2006.08.5696
pubmed: 17687155
Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic syndromes. Blood. 2012;120(12):2454–65. https://doi.org/10.1182/blood-2012-03-420489 .
doi: 10.1182/blood-2012-03-420489
pubmed: 22740453
pmcid: 4425443
Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for Myelodysplastic syndromes. NEJM Evid. 2022;1(7):EVIDoa2200008. https://doi.org/10.1056/EVIDoa2200008 .
doi: 10.1056/EVIDoa2200008
pubmed: 38319256
Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385–95. https://doi.org/10.1182/blood-2007-03-082404 .
doi: 10.1182/blood-2007-03-082404
pubmed: 17726160
Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820–9. https://doi.org/10.1200/JCO.2011.35.6394 .
doi: 10.1200/JCO.2011.35.6394
pubmed: 22331955
pmcid: 4874200
Solé F, Luño E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90(9):1168–78.
pubmed: 16154839
Pozdnyakova O, Miron PM, Tang G, et al. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 2008;113(12):3331–40. https://doi.org/10.1002/cncr.23977 .
doi: 10.1002/cncr.23977
pubmed: 18988232
Berggren DM, Folkvaljon Y, Engvall M, et al. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register. Br J Haematol. 2018;181(5):614–27. https://doi.org/10.1111/bjh.15243 .
doi: 10.1111/bjh.15243
Miyazaki Y, Tuechler H, Sanz G, et al. Differing clinical features between Japanese and caucasian patients with myelodysplastic syndromes: analysis from the International Working Group for Prognosis of MDS. Leuk Res. 2018;73:51–7. https://doi.org/10.1016/j.leukres.2018.08.022 .
doi: 10.1016/j.leukres.2018.08.022
pubmed: 30219650
Wang X, Liu W, Wang M, et al. Cytogenetic characteristics of 665 patients with myelodysplastic syndrome in China: a single-center report. Oncol Lett. 2021;21(2):126. https://doi.org/10.3892/ol.2020.12387 .
doi: 10.3892/ol.2020.12387
pubmed: 33552247
Yan X, Wang L, Jiang L, et al. Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes. Cancer Med. 2021;10(5):1759–71. https://doi.org/10.1002/cam4.3786 .
doi: 10.1002/cam4.3786
pubmed: 33609081
pmcid: 7940222
Qu S, Xu Z, Zhang Y, et al. Impacts of cytogenetic categories in the revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study. Leuk Lymphoma. 2012;53(5):940–6. https://doi.org/10.3109/10428194.2011.634049 .
doi: 10.3109/10428194.2011.634049
pubmed: 22023524
Jung SW, Lee SY, Jekarl DW, et al. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution. Leuk Res. 2011;35(6):735–40. https://doi.org/10.1016/j.leukres.2010.11.009 .
doi: 10.1016/j.leukres.2010.11.009
pubmed: 21146871
Phrommin S, Tantiworawit A, Rattanathammethee T, et al. Chromosomal abnormalities in Myelodysplastic Syndrome patients in Upper Northern Thailand. Asian Pac J Cancer Prev. 2020;21(3):639–45. https://doi.org/10.31557/APJCP.2020.21.3.639 .
doi: 10.31557/APJCP.2020.21.3.639
pubmed: 32212788
pmcid: 7437337
Gmidène A, Sennana H, Fenaux P, et al. Cytogenetic abnormalities in Tunisian de novo myelodysplastic syndrome: a comparison with other populations. Leuk Res. 2008;32(12):1824–9. https://doi.org/10.1016/j.leukres.2008.05.002 .
doi: 10.1016/j.leukres.2008.05.002
pubmed: 18556065
Elnahass Y, Youssif L. Cytogenetic features in primary myelodysplastic syndrome Egyptian patients. J Adv Res. 2018;10:77–83. https://doi.org/10.1016/j.jare.2018.02.002 .
doi: 10.1016/j.jare.2018.02.002
pubmed: 30046476
pmcid: 6057444
Paridar M, Zibara K, Ahmadi SE, et al. Clinico-Hematological and cytogenetic spectrum of adult myelodysplastic syndrome: the first retrospective cross-sectional study in Iranian patients. Mol Cytogenet. 2021;14(1):24. https://doi.org/10.1186/s13039-021-00548-z .
doi: 10.1186/s13039-021-00548-z
pubmed: 33964952
pmcid: 8106119
Mahmood R, Altaf C, Ahmed P, Khan SA, Malik HS. Myelodysplastic syndrome in Pakistan: clinicohematological characteristics, Cytogenetic Profile, and risk stratification. Turk J Haematol. 2018;35(2):109–15. https://doi.org/10.4274/tjh.2017.0130 .
doi: 10.4274/tjh.2017.0130
pubmed: 28588002
pmcid: 5972332
Vundinti BR, Kerketta L, Jijina F, Ghosh K. Cytogenetic study of myelodysplastic syndrome from India. Indian J Med Res. 2009;130(2):155–9.
pubmed: 19797812
Gupta R, Rahman K, Singh MK, Kumari S, Yadav G, Nityanand S. Clinico-Pathological Spectrum and Novel Karyotypic findings in Myelodysplastic Syndrome: experience of Tertiary Care Center in India. Mediterr J Hematol Infect Dis. 2017;9(1):e2017048. https://doi.org/10.4084/MJHID.2017.048 .
doi: 10.4084/MJHID.2017.048
pubmed: 28894557
pmcid: 5584769
Dal Cin P. Metaphase harvest and cytogenetic analysis of malignant hematological specimens. Curr Protoc Hum Genet. 2003;Chap. 10:Unit 10.2. https://doi.org/10.1002/0471142905.hg1002s36 .
McGowan-Jordan J, Simons A, Schmid MISCN. 2016: An International System for Human Cytogenomic Nomenclature. Basel: S.Karger, 2016. In: 2016. https://doi.org/10.1159/ISBN.978-3-318-05979-3 .
Li L, Liu XP, Nie L, et al. Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients. Leuk Res. 2009;33(9):1194–8. https://doi.org/10.1016/j.leukres.2008.11.021 .
doi: 10.1016/j.leukres.2008.11.021
pubmed: 19128829
Rashid A, Khurshid M, Shaikh U, Adil S. Chromosomal abnormalities in primary myelodysplastic syndrome. J Coll Physicians Surg Pak. 2014;24(9):632–5.
pubmed: 25233965
Anwar N, Arshad A, Nadeem M, et al. Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast. Mol Cytogenet. 2017;10:17. https://doi.org/10.1186/s13039-017-0318-4 .
doi: 10.1186/s13039-017-0318-4
pubmed: 28491138
pmcid: 5423005
Avgerinou C, Alamanos Y, Zikos P, et al. The incidence of myelodysplastic syndromes in Western Greece is increasing. Ann Hematol. 2013;92(7):877–87. https://doi.org/10.1007/s00277-013-1712-6 .
doi: 10.1007/s00277-013-1712-6
pubmed: 23572136
pmcid: 3674340
Mądry K, Machowicz R, Waszczuk-Gajda A, et al. Demographic, hematologic, and clinical features of Myelodysplastic Syndrome patients: results from the First Polish Myelodysplastic Syndrome Registry. Acta Haematol. 2015;134(2):125–34. https://doi.org/10.1159/000375149 .
doi: 10.1159/000375149
pubmed: 25925777
Chihara D, Ito H, Katanoda K, Shibata A, Matsuda T, Sobue T, Matsuo K. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014;24(6):469 – 73 https://doi.org/10.2188/jea.je20140042 Epub 2014 Aug 2 PMID: 25088696; PMCID: PMC4213221.
Chen B, Zhao WL, Jin J, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in western countries. Leukemia. 2005;19(5):767–75. https://doi.org/10.1038/sj.leu.2403688 .
doi: 10.1038/sj.leu.2403688
pubmed: 15759035
Lee JH, Lee JH, Shin YR, et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia. 2003;17(2):305–13. https://doi.org/10.1038/sj.leu.2402798 .
doi: 10.1038/sj.leu.2402798
pubmed: 12592327
Jiang Y, Eveillard JR, Couturier MA, et al. Asian Population is more Prone to develop high-risk myelodysplastic syndrome, Concordantly with their propensity to exhibit high-risk cytogenetic aberrations. Cancers (Basel). 2021;13(3):481. https://doi.org/10.3390/cancers13030481 .
doi: 10.3390/cancers13030481
pubmed: 33513838
Malcovati L, Porta MGD, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594–603. https://doi.org/10.1200/JCO.2005.01.7038 .
doi: 10.1200/JCO.2005.01.7038
pubmed: 16186598
Germing U, Strupp C, Kuendgen A, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica. 2006;91(12):1596–604.
pubmed: 17145595
Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 2008;87(7):515–26. https://doi.org/10.1007/s00277-008-0483-y .
doi: 10.1007/s00277-008-0483-y
pubmed: 18414863
pmcid: 2413090
Mansoor AM, Bharadwaj TP, Sethuraman S, et al. Analysis of karyotype, SCE, and point mutation of RAS oncogene in Indian MDS patients. Cancer Genet Cytogenet. 1993;65(1):12–20. https://doi.org/10.1016/0165-4608(93)90052-n .
doi: 10.1016/0165-4608(93)90052-n
pubmed: 8431911
Dakshinamurthy AG, Novitzky N, Bharadwaj R, Prakhya BM. Cytogenetic analysis of 52 Indian patients with de novo myelodysplastic syndromes-a comparative analysis of results with reports from Asia. Ann Hematol. 2005;84(5):298–303. https://doi.org/10.1007/s00277-004-0997-x .
doi: 10.1007/s00277-004-0997-x
pubmed: 15742188
Varma N, Varma S. Proliferative indices, cytogenetics, Immunophenotye and other Prognostic parameters in Myelodysplastic syndromes. Indian J Pathol Microbiol. 2008;51(1):97–101. https://doi.org/10.4103/0377-4929.40416 .
doi: 10.4103/0377-4929.40416
pubmed: 18417875
Chaubey R, Sazawal S, Dada R, Mahapatra M, Saxena R. Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res. 2011;134:452–7.
pubmed: 22089606
pmcid: 3237242
Narayanan S. Clinical, hematological, and cytogenetic profile of adult myelodysplastic syndrome in a tertiary care center. J Blood Med. 2017;8:21–7. https://doi.org/10.2147/JBM.S129111 .
doi: 10.2147/JBM.S129111
pubmed: 28260960
pmcid: 5328424
Gangat N, Patnaik MM, Begna K, et al. Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. Am J Hematol. 2013;88(8):690–3. https://doi.org/10.1002/ajh.23477 .
doi: 10.1002/ajh.23477
pubmed: 23686868
Voso MT, Fenu S, Latagliata R, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol. 2013;31(21):2671–7. https://doi.org/10.1200/JCO.2012.48.0764 .
doi: 10.1200/JCO.2012.48.0764
pubmed: 23796988
Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29(7):1502–13. https://doi.org/10.1038/leu.2015.55 .
doi: 10.1038/leu.2015.55
pubmed: 25721895
Hou HA, Tsai CH, Lin CC, et al. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer J. 2018;8(4):39. https://doi.org/10.1038/s41408-018-0074-7 .
doi: 10.1038/s41408-018-0074-7
pubmed: 29618722
pmcid: 5884776
Du MY, Xu M, Deng J, et al. Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population. J Cancer. 2020;11(2):508–19. https://doi.org/10.7150/jca.30363 .
doi: 10.7150/jca.30363
pubmed: 31897246
pmcid: 6930433